Biotech Stocks Well-Positioned For Fourth Quarter

Oct. 11, 2022 8:30 AM ETAKRO, AMGN, BIIB, BLUE, KRTX, NONOF, NVO, PFE, RYTM, IBB, XBI3 Comments

Summary

  • Biotechs are relatively better positioned in this fourth quarter compared to the broader market.
  • Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach.
  • Biotechs benefit if a slowdown pushes the longer-term yields lower.
  • M&A, partnerships, and breakthrough treatments provide further support. However, 10-year yields must stabilize and trend down for longer-lasting gains.
  • I do much more than just articles at Prudent Healthcare: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »

Abstract Genetics Disease

koto_feja

Biotech Pulse

Biotechs have been outperforming the broader market in this decline phase of the bear market. While most major indexes made new lows for the year or retested prior lows set in June, biotech indexes have resisted declining back

Biotech Performance and the 10-year Yield

Biotech Performance and the 10-year Yield (PrudentBiotech.com)

The Best Time to Plant an Oak was 20 Years Ago. The Next Best Time is Now!

Prudent Healthcare is focused on seizing the promise of healthcare through its quantitatively-driven model portfolio. Based on a systematic investing approach, the monthly updated portfolio targets strong risk-adjusted returns outperforming benchmarks.

  • How is the Healthcare portfolio doing?
  • Leading Healthcare Service, up 64% in 2021
  • Leverage the strengths of quantitative investing
  • An approach with a strong track record
  • Fully refundable offer
  • Understand how it works & if it can work for you

The Market Doesn't Wait!

To learn more about building wealth & claim your free trial, please click here.

__________________________________

This article was written by

Tarun Chandra, CFA profile picture
4.67K Followers
A healthcare growth portfolio with a record of consistently strong returns

I have worked as an Analyst on both the Buy (Asset Management) and Sell (Investment Brokerage) sides, as well as in Strategy and Finance roles for technology services companies. For many years, I have been publishing risk-adjusted, return-driven quantitative model portfolios.


We have 3 services - Prudent Healthcare, which is available only on Seeking Alpha, Prudent Biotech, and Prudent Small Cap. You may even register for a Free Monthly Pick from the model portfolios for biotech and small caps on those pages.

We have collaborated with Seeking Alpha to launch a Prudent Healthcare model portfolio, available exclusively in the SA Marketplace. It's a monthly service with a leading track record in healthcare performance.

If you have any questions, please feel free to write to support@PrudentHealthcare.com.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Although there are no personal account positions, SOME STOCKS MENTIONED CAN ALREADY BE PART OF THE PORTFOLIOS OF FAMILY AND ASSOCIATES and retirement accounts like IRAs and can be bought/sold in the next 72 hours. The stocks mentioned may already be part of the Biotech, Healthcare, or Small Cap model portfolios.

As always, kindly do your due diligence. Biotechs and small caps carry a higher risk of losses than the broader market. Opinions can change with time and additional data, with no obligation to update. Companies mentioned here may not be favored in the future as market trend changes and/or new information emerges, and no relevant portfolio updates will be provided unless you are a model portfolio subscriber.

Prudent Biotech, Prudent Healthcare, Prudent Small Cap, Graycell Advisors, or any other associated names and entities are not registered investment advisors (RIA) and publish quantitative-driven model portfolios for investors and RIAs. Stocks mentioned in the article may be in the past, present, or in the future, be part of the various model portfolios for subscribers. Past performance is not a guarantee of future results. The information here is only provided for a general informational purpose and not as a recommendation and is not guaranteed to be complete or accurate.

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.